Payment overview · 2025
General Payments
$787.96
35 reported records · 7 companies
Healthcare provider profile · identity verified
Alexander Bakis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1366510083
Verified facts
What the public records show
CMS Open Payments records show Alexander Bakis, M.D. received $787.96 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Prolia, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $230.29 | 29.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $171.40 | 21.8% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $147.20 | 18.7% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $122.84 | 15.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.33 | 8.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.67 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.23 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $787.96 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $147.20 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $130.39 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $130.39 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $122.84 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $90.98 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.18 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $78.50 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.33 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 68 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 186 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 269 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
269 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 12 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
160 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 760 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 496 | 74 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 403 | 69 |
| Losartan Potassium | Losartan Potassium | 397 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 52 |
| Carvedilol | Carvedilol | 308 | 46 |
| Metformin Hcl | Metformin Hcl | 292 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 42 |
| Linzess | Linaclotide | 269 | 34 |
| Omeprazole | Omeprazole | 248 | 47 |
| Vascepa | Icosapent Ethyl | 223 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 41 |
| Irbesartan | Irbesartan | 207 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 193 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 188 | 37 |
| Eliquis | Apixaban | 186 | 28 |
| Jardiance | Empagliflozin | 177 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 23 |
| Zenpep | Lipase/Protease/Amylase | 160 | 19 |
| Simvastatin | Simvastatin | 158 | 21 |
| Clonidine Hcl | Clonidine Hcl | 134 | 40 |
| Furosemide | Furosemide | 130 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 25 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 118 | 12 |
| Allopurinol | Allopurinol | 111 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 19 |
| Meloxicam | Meloxicam | 98 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 12 |
| Januvia | Sitagliptin Phosphate | 95 | 12 |
| Synthroid | Levothyroxine Sodium | 95 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 92 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 33 |
| Memantine Hcl | Memantine Hcl | 91 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 91 | 11 |
| Buspirone Hcl | Buspirone Hcl | 89 | 19 |
| Edarbi | Azilsartan Medoxomil | 85 | 11 |
| Azithromycin | Azithromycin | 81 | 57 |
| Gabapentin | Gabapentin | 79 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 14 |
| Finasteride | Finasteride | 74 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 72 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 11 |
| Creon | Lipase/Protease/Amylase | 68 | 13 |
| Celecoxib | Celecoxib | 67 | 19 |
| Meclizine Hcl | Meclizine Hcl | 66 | 18 |
| Digoxin | Digoxin | 63 | suppressed |
| Felodipine Er | Felodipine | 63 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | suppressed |
| Glipizide Er | Glipizide | 61 | suppressed |
| Atenolol | Atenolol | 56 | 11 |
| Famotidine | Famotidine | 56 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Naproxen | Naproxen | 56 | 39 |
| Ozempic | Semaglutide | 56 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 51 | suppressed |
| Valsartan | Valsartan | 51 | suppressed |
| Ketoconazole | Ketoconazole | 50 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | suppressed |
| Lorazepam | Lorazepam | 47 | 21 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 18 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 11 |
| Dexilant | Dexlansoprazole | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | 11 |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Lisinopril | Lisinopril | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Prolia | Denosumab | 29 | 19 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Crestor | Rosuvastatin Calcium | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $787.96 · 35 records | ABBVIE INC. | CREON, ELIQUIS, EVENITY, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error